1. Home
  2. OMER vs CLNE Comparison

OMER vs CLNE Comparison

Compare OMER & CLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • CLNE
  • Stock Information
  • Founded
  • OMER 1994
  • CLNE 2001
  • Country
  • OMER United States
  • CLNE United States
  • Employees
  • OMER N/A
  • CLNE N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • CLNE Natural Gas Distribution
  • Sector
  • OMER Health Care
  • CLNE Utilities
  • Exchange
  • OMER Nasdaq
  • CLNE Nasdaq
  • Market Cap
  • OMER 667.0M
  • CLNE 692.6M
  • IPO Year
  • OMER 2009
  • CLNE 2007
  • Fundamental
  • Price
  • OMER $7.88
  • CLNE $2.71
  • Analyst Decision
  • OMER Buy
  • CLNE Strong Buy
  • Analyst Count
  • OMER 3
  • CLNE 4
  • Target Price
  • OMER $9.00
  • CLNE $5.38
  • AVG Volume (30 Days)
  • OMER 1.0M
  • CLNE 1.9M
  • Earning Date
  • OMER 11-13-2024
  • CLNE 11-06-2024
  • Dividend Yield
  • OMER N/A
  • CLNE N/A
  • EPS Growth
  • OMER N/A
  • CLNE N/A
  • EPS
  • OMER N/A
  • CLNE N/A
  • Revenue
  • OMER N/A
  • CLNE $413,396,000.00
  • Revenue This Year
  • OMER N/A
  • CLNE N/A
  • Revenue Next Year
  • OMER N/A
  • CLNE $1.69
  • P/E Ratio
  • OMER N/A
  • CLNE N/A
  • Revenue Growth
  • OMER N/A
  • CLNE N/A
  • 52 Week Low
  • OMER $2.61
  • CLNE $2.17
  • 52 Week High
  • OMER $12.65
  • CLNE $4.13
  • Technical
  • Relative Strength Index (RSI)
  • OMER 45.47
  • CLNE 42.49
  • Support Level
  • OMER $7.33
  • CLNE $2.65
  • Resistance Level
  • OMER $12.65
  • CLNE $2.80
  • Average True Range (ATR)
  • OMER 1.06
  • CLNE 0.15
  • MACD
  • OMER -0.63
  • CLNE -0.01
  • Stochastic Oscillator
  • OMER 10.34
  • CLNE 10.71

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About CLNE Clean Energy Fuels Corp.

Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas, liquefied natural gas, and renewable natural gas as an alternative fuel for vehicles. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The company operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. The company also builds, operates, and maintains natural gas fueling stations for customers. The company's target markets include heavy-duty trucking, airports, public transit, institutional energy users, and government fleets.

Share on Social Networks: